Login to Your Account



Hold the Liver: Achillion’s HCV Drug Still Stalled; Future Looks Dicey

By Randy Osborne
Staff Writer

Monday, September 30, 2013
As Achillion Pharmaceuticals Inc.’s stock reeled from the FDA’s refusal to lift the clinical hold imposed this summer on the hepatitis C virus (HCV) candidate sovaprevir because of elevated liver enzymes, analysts mulled the larger meaning and the company sought to reassure investors during a conference call.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription